Navigation Links
febit Receives U.S. Patent for Microfluidic Extraction Method
Date:5/27/2008

febit Expands its Leading Position in Next-Generation Sequencing

LEXINGTON, Mass. and HEIDELBERG, Germany, May 27 /PRNewswire/ -- febit today announced the receipt of US patent #7320862 on its microfluidic microarray-based method for extraction of DNA and RNA.

This method forms the basis of a novel technology that enables the expanded use of next-generation sequencers in genomic research. Further investigation of the human genome by resequencing will particularly benefit from the new method: febit uses its microfluidic biochip system for sequence-based selective isolation of nucleic acids from genomic samples. This new approach to high-throughput sequencing essentially relies on high-density microarray biochips with flexible design, a technology established by febit several years ago. The newly patented method is known as hybselect, targeted sequencing or sequence capture. Using this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing.

febit microfluidic biochip systems have been successfully used for several years in DNA analysis and synthesis. The latest patent was now granted in the US, patents in Europe and other foreign countries will soon follow.

febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips, an area where febit holds several key patents. Using a focussed application strategy, febit has been able to secure intellectual property rights on important product components, processes and evolving technologies.

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.
http://www.febit.com

Contact:

febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300 david.schull@russopartnersllc.com

eva.sterzel@febit.de wendy.lau@russopartnersllc.com


'/>"/>
SOURCE febit
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
2. febit First to Offer miRBase 11.0 Biochip
3. febit Forms Scientific Advisory Board
4. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
5. Prime Therapeutics Receives VIPPS Accreditation
6. Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries
7. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
8. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
9. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
10. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
11. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... Lady ... eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah sought ... a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help with ...
(Date:5/24/2016)... Mass. (PRWEB) , ... May 24, 2016 , ... ... heart attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester ... cells into engines of wound healing and tissue regeneration. , The novel method, ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Last week, Callan ... corporate executives and entrepreneurs, held The Future of San Diego Life Science event at ... Diego life science community attended the event with speakers Dr. Rich Heyman, former CEO ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):